rivaroxaban and Jaundice

Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation. Because of its efficacy and once-a-day dosing, it is commonly preferred in patients with nonvalvular atrial fibrillation and intolerance to warfarin in clinical practice. However, it can result in some adverse effects such as bleeding, rashes and liver injury. Here, we described a very rare adverse reaction of rivaroxaban, jaundice due to intrahepatic cholestasis, appeared in a 71-year-old male patient after taking rivaroxaban.

Topics: Aged; Anticoagulants; Antihypertensive Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Cholestasis, Intrahepatic; Humans; Hypertension; Jaundice; Liver; Male; Perindopril; Propanolamines; Rivaroxaban; Severity of Illness Index; Treatment Outcome